Q-omics provides the consensus-scored TRAJ34 profile across patient tissues and cancer cell-line models. TRAJ34 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAJ34 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRAJ34 RNA expression shows 11,101 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where TRAJ34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ34 survival associations across molecular data types. TRAJ34 RNA expression shows survival associations in the most cancer types (13), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ34 RNA expression–survival associations across cancer types. High TRAJ34 expression shows unfavorable associations in ACC, MESO and KICH, but favorable associations in HNSC, ESCA and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAJ34 RNA expression.
This table summarizes TRAJ34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ34 shows lower tumor expression in COAD and higher tumor expression in KIRC, ESCA and STAD. The KIRC box plot shows higher TRAJ34 RNA expression in tumor versus normal tissue (log2 FC = +0.174, t-test p = .018).
This table shows molecular features associated with TRAJ34 in patient tissues and cancer cell lines. In patient samples, TRAJ34 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
